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Kynurenic acid (KYNA), an astrocyte-derived, endogenous antagonist of α7 nicotinic
acetylcholine and excitatory amino acid receptors, regulates glutamatergic, GABAergic,
cholinergic and dopaminergic neurotransmission in several regions of the rodent
brain. Synthesis of KYNA in the brain and elsewhere is generally attributed to the
enzymatic conversion of L-kynurenine (L-KYN) by kynurenine aminotransferases (KATs).
However, alternative routes, including KYNA formation from D-kynurenine (D-KYN) by
D-amino acid oxidase (DAAO) and the direct transformation of kynurenine to KYNA
by reactive oxygen species (ROS), have been demonstrated in the rat brain. Using
the rat cerebellum, a region of low KAT activity and high DAAO activity, the present
experiments were designed to examine KYNA production from L-KYN or D-KYN by
KAT and DAAO, respectively, and to investigate the effect of ROS on KYNA synthesis.
In chemical combinatorial systems, both L-KYN and D-KYN interacted directly with
peroxynitrite (ONOO−) and hydroxyl radicals (OH ), resulting in the formation of KYNA. In•
tissue homogenates, the non-specific KAT inhibitor aminooxyacetic acid (AOAA; 1 mM)
reduced KYNA production from L-KYN and D-KYN by 85.1 ± 1.7% and 27.1 ± 4.5%,
respectively. Addition of DAAO inhibitors (benzoic acid, kojic acid or 3-methylpyrazole-
5-carboxylic acid; 5 µM each) attenuated KYNA formation from L-KYN and D-KYN by
∼35% and ∼66%, respectively. ONOO− (25 µM) potentiated KYNA production from
both L-KYN and D-KYN, and these effects were reduced by DAAO inhibition. AOAA
attenuated KYNA production from L-KYN + ONOO− but not from D-KYN + ONOO−.
In vivo, extracellular KYNA levels increased rapidly after perfusion of ONOO− and, more
prominently, after subsequent perfusion with L-KYN or D-KYN (100 µM). Taken together,
these results suggest that different mechanisms are involved in KYNA production in the
rat cerebellum, and that, specifically, DAAO and ROS can function as alternative routes
for KYNA production.
Keywords: D-amino acid oxidase, kynurenine, microdialysis, oxidative stress, reactive oxygen species
Abbreviations: AOAA, Aminooxyacetic acid; D-KYN, D-Kynurenine; DAAO, D-amino acid oxidase; DMSO,
Dimethylsulfoxide; D-Trp, D-tryptophan; 3-HK, 3-Hydroxykynurenine; L-KYN, L-Kynurenine; KYNA, Kynurenic acid; KP,
Kynurenine pathway; KATs, Kynurenine aminotransferases; MPC, 3-Methylpyrazole-5-carboxylic acid; NMDA, N-methyl-
D-aspartate; ONOO−, peroxynitrite; OH•, Hydroxyl radical; PFC, Prefrontal cortex; ROS, Reactive oxygen species.
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Introduction
In the mammalian brain, the tryptophan metabolite kynurenic
acid (KYNA) functions as an endogenous antagonist of the
α7 nicotinic acetylcholine receptor (α7nAChR; Hilmas et al.,
2001) and the N-methyl-D-aspartate receptor (NMDAR; Kessler
et al., 1989; Alkondon et al., 2011). KYNA, which is also
a ligand of the G protein-coupled receptor GPR35 (Wang
et al., 2006) and can activate the aryl hydrocarbon receptor
(DiNatale et al., 2010), is considered a neuromodulator
since fluctuations in its endogenous levels bi-directionally
influence extracellular concentrations of glutamate, dopamine
and γ-aminobutyric acid (GABA) levels in the rat brain
(Carpenedo et al., 2001; Rassoulpour et al., 2005; Amori
et al., 2009; Wu et al., 2010; Pocivavsek et al., 2011; Beggiato
et al., 2014), and reductions in KYNA formation result in
increased levels of extracellular acetylcholine (Zmarowski et al.,
2009). Notably, increases in cerebral KYNA levels, which are
seen in the aged brain (Moroni et al., 1988; Gramsbergen
et al., 1992; Heyes et al., 1992; Kepplinger et al., 2005)
and in several major neurological and psychiatric diseases
(Baran et al., 1999; Schwarcz et al., 2001; Guidetti et al.,
2004; Kepplinger et al., 2005; Sathyasaikumar et al., 2011),
have been suggested to be causally related to cognitive
impairments (Wonodi and Schwarcz, 2010; Pocivavsek et al.,
2012, 2014).
In the brain as elsewhere, KYNA synthesis is attributed to
several distinct kynurenine aminotransferases (KATs), which
catalyze the irreversible transamination of L-kynurenine
(L-KYN) to KYNA (Okuno et al., 1991; Guidetti et al.,
2007a; Han et al., 2010). Of these enzymes, KAT II, which
is preferentially contained in astrocytes (Guidetti et al., 2007b),
has received most attention since it appears to be responsible
for the rapid mobilization of newly produced KYNA (Schwarcz
et al., 2012). However, alternative routes of KYNA production
exist under physiological conditions. For example, KYNA can
be formed from D-kynurenine (D-KYN) through oxidative
deamination by D-amino acid oxidase (DAAO; Loh and Berg,
1971; Ishii et al., 2010), as demonstrated in the brain and
in peripheral tissues of mice, rats and rabbits (Mason and
Berg, 1952; Loh and Berg, 1971; Fukushima et al., 2009; Wang
et al., 2012) and, recently, in human brain tissue (Pérez-de la
Cruz et al., 2012). However, KATs also recognize D-KYN as
a substrate and can catalyze the de novo formation of KYNA
from D-KYN in the brain in vivo (Pérez-de la Cruz et al.,
2012).
Neosynthesis of KYNA can also involve the transamination
of L-tryptophan by tryptophan-2-oxoglutarate aminotransferase
(Hardeland, 2008). Thus, the enolic form of the primary
reaction product, indole-3-pyruvic acid, is highly susceptible to
reactive oxygen species (ROS) and readily undergoes pyrrole
ring cleavage by interaction with oxygen intermediaries. The
transiently formed product then spontaneously cyclizes to
generate KYNA. L-KYN, too, is easily oxidized and can be
converted to KYNA in the presence of hydrogen peroxide
(H2O2), a process that is substantially enhanced by horseradish
peroxidase (Zsizsik and Hardeland, 2001b). In biological systems,
too, KYNA formation can result from direct reactions of either
indole-3-pyruvic acid or KYN with ROS. Examples include
KYNA synthesis in several rat organs after incubation with
indole-3-pyruvic acid under conditions that are conducive to
the generation of free radicals (ascorbate/Fe/H2O2) (Politi et al.,
1991), and KYNA production from L-KYN in homogenates
of Lingulodinium polyedrum exposed to light and various ROS
generators (Zsizsik and Hardeland, 2001a, 2002).
The present study was designed to examine the various routes
of KYNA neosynthesis from L-KYN and D-KYN in parallel.
Using the rat cerebellum, which was selected on the basis of
its high DAAO content and relatively low KAT activity (Baran
and Schwarcz, 1993; Horiike et al., 1994; Moreno et al., 1999;
Verrall et al., 2007), we also compared KYNA formation in the
presence or absence of ROS. Our results demonstrate that de
novo KYNA formation can involve different mechanisms, and
that ROS should be considered a viable alternative for KYNA
production from both L-KYN and D-KYN under physiological
and, possibly, pathological conditions.
Materials and Methods
Animals
Adult, male Wistar rats (280–320 g), obtained from the vivarium
of the National Autonomous University of Mexico (Mexico
City), were used for this study. The animals were housed five per
cage in acrylic cages and provided with a standard commercial
rat diet (Laboratory rodent diet 5001, PMI Feeds Inc., Richmond,
IN, USA) and water ad libitum. All rats were housed in the same
room under identical environmental conditions, i.e., temperature
(25 ± 3◦C), humidity (50 ± 10%) and lighting (12 h light/dark
cycles).
Animals were killed by decapitation, and their tissues were
immediately dissected out on ice and preserved at −70◦C. All
procedures with animals were carried out according to the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals, and the local guidelines on the ethical use
of animals from the Health Ministry of Mexico. All efforts were
made to minimize animal suffering during the study.
Materials
KYNA, L-KYN, D-KYN, dimethylsulfoxide (DMSO), DL-
penicillamine, diethylenetriaminepentaacetic acid (DTPA),
H2O2, ethylenediaminetetraacetic acid (EDTA),
3-methylpyrazole-5-carboxylic acid (MPC), kojic acid and
benzoic acid were obtained from Sigma Aldrich Company
(St. Louis, MO, USA). All other chemicals were of the highest
commercially available purity. Solutions were prepared using
deionized water obtained from a Milli-RQ (Millipore) purifier
system.
ONOO− Synthesis
ONOO− was synthesized as previously described (Beckman
et al., 1994). Five ml of an acidic solution (0.6 M HCl) of H2O2
(0.7 M) were briefly mixed with 5 ml of 0.6 M KNO2 in an
ice bath, and the reaction was quenched with 5 ml of ice-cold
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1.2 M NaOH. Residual H2O2 was removed using granular MnO2
pre-washed with 1.2 M NaOH, and the reaction mixture was
then left overnight at −20◦C. The resulting yellow liquid layer
on top of the frozen mixture was collected for the experiment
immediately before use, and adjusted to a final concentration
of 50 µM using Ringer solution (144 mM NaCl, 4.8 mM KCl,
1.2 mM MgSO4 and 1.7 mM CaCl2, pH 7.2). Concentrations
of ONOO− were determined in quartz cuvettes using a molar
extinction coefficient of 302 nm = 1670 M−1cm−1 (Hughes and
Nicklin, 1970).
Chemical Combinatorial Assays
The ability of OH• to produce KYNA in combination with
L-KYN or D-KYN was examined using the Fe3+-EDTA-H2O2
system (Halliwell et al., 1987; Floriano-Sánchez et al., 2006). The
system contained L-KYN or D-KYN (20 µM each), 0.2 mM
ascorbic acid, 0.2 mM FeCl3, 0.2 mM EDTA, 1 mM H2O2
and 20 mM phosphate buffer (pH 7.4) in a final volume of
500 µl. Additional tubes were incubated in the presence of
10% DMSO to evaluate the effect of an OH• scavenger on
KYNA production. Samples were incubated for 15 min at
room temperature. After incubation, KYNA production was
quantified by high performance liquid chromatography (HPLC;
see below).
Interactions between the two KYN enantiomers and ONOO−
were determined using ONOO− synthetized in our laboratory
(Lugo-Huitrón et al., 2011a). Briefly, the reaction mixture (in a
final volume of 500 µl in HPLC grade water) consisted of L-KYN
or D-KYN (20 µM each) and 25 µM ONOO−. In separate tubes,
the ONOO− scavenger DL-penicillamine (300 µM) (Floriano-
Sánchez et al., 2006); was added to evaluate its effect on KYNA
formation. After 15 min of incubation at room temperature,
KYNA levels were determined by HPLC.
In vitro Studies with Tissue
Cerebella were dissected out and immediately weighed and
frozen on dry ice. Tissues were then homogenized (1:10, w/v) in
Krebs buffer (118.5 mM NaCl, 4.75 mM KCl, 1.77 mM CaCl2,
1.18 mM MgSO4, 12.9 mM NaH2PO4, 3 mM Na2HPO4 and
5 mM glucose; pH 7.4). In order to evaluate KYNA production by
ONOO−, 80 µl of the tissue homogenate were incubated for 2 h
at 37◦C in the presence of DAAO inhibitors (MPC, benzoic acid
or kojic acid) or AOAA. L-KYN or D-KYN (100 µM) were added
to the tissue homogenate, and each inhibitor (final concentration:
1 mM) was assessed in the presence or absence of ONOO−
(25 µM) in a final volume of 200 µl. After incubation, samples
were centrifuged for 10 min at 6,000 × g, and the supernatants
were diluted 1:5 (v/v) for KYNA determination.
Microdialysis
Rats were anesthetized with a mixture of ketamine (80 mg/kg)
and xylazine (100 mg/kg) (i.p.) and placed in a stereotaxic
frame. A guide cannula was positioned and secured to the
skull with stainless steel screws and acrylic dental cement at
the following coordinates: AP: 11.0 mm posterior to bregma, L:
±2.0 mm from the midline, V: 4.0 mm below the dura. Three
days later, a microdialysis probe (MD-220, membrane length:
2 mm; BASi, West Lafayette, IN, USA) was inserted through
the guide cannula to protrude into the cerebellar cortex, and
connected to a microperfusion pump set at a speed of 2 µl/min.
Microdialysis samples were collected every 30 min. A stable
baseline was first established by perfusing Ringer solution (pH
7.4) for 2 h. Production of KYNA from either L-KYN or D-
KYN was then assessed by perfusing the bioprecursors, diluted in
Ringer solution, for 2 h. The effect of ONOO− was examined by
perfusing the compound for 30 min prior to the administration
of either L-KYN or D-KYN. After the discontinuation of the
experimental interventions, Ringer solution was perfused for an
additional 4 h. Animals were then killed by decapitation, and
the cerebellum was dissected to confirm the proper placement
of the microdialysis probe. Microdialysate samples were diluted
as needed and then analyzed directly by HPLC. Data were not
corrected for recovery from the microdialysis probe.
KYNA Analysis
KYNA was measured by HPLC with fluorometric detection.
Briefly, 20 µl of the sample (after either in vitro incubations
or perfusions in vivo) were injected onto a 3-µm C18 reverse
phase column (80 × 4.6 mm; ESA, Chelmsford, MA, USA), and
KYNA was isocratically eluted using a mobile phase containing
250 mM of zinc acetate, 50 mM sodium acetate and 3% of
acetonitrile (pH adjusted to 6.2 with glacial acetic acid) at a
flow rate of 1 ml/min. KYNA was detected fluorimetrically
(excitation wavelength: 344 nm, emission wavelength: 398 nm,
S200 fluorescence detector; Perkin-Elmer, Waltham, MA, USA).
The retention time of KYNA was∼7 min.
Data Analysis
One-way analysis of variance (ANOVA) followed by
Bonferroni’s post hoc test was used to analyze the effect of the
different treatments used in vitro. In microdialysis experiments,
the average of five samples collected immediately prior to the
administration of test compounds was defined as the baseline
value (100%). The effect of either L-KYN or D-KYN, alone
or after in vivo pretreatment with ONOO−, was analyzed by
two-way ANOVA with repeated measures followed by post hoc
tests: a Student’s t-test was used to compare two treatments at a
specific time point, and a paired Student’s t-test was used when
comparing the effect of a treatment at two specific times. In all
cases, a P-value<0.05 was considered significant.
Results
KYNA Production by Interaction of L-KYN or
D-KYN with OH• and ONOO− in Synthetic
Systems
Co-incubation of L-KYN or D-KYN (20 µM each) with OH•
and ONOO−, respectively, resulted in the formation of KYNA
in vitro. As illustrated in Figure 1, incubation for 15 min led
to the de novo production of KYNA. KYNA was undetectable
in the control solutions containing the enantiomers alone, and
no KYNA was measurable when OH• was incubated on its own
(not shown). Addition of the OH• scavenger DMSO (10%),
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FIGURE 1 | Incubation of OH• (A) or ONOO− (B) with L-KYN or
D-KYN (20 µM each) for 15 min in vitro results in the de novo
production of KYNA in the absence of tissue. Co-incubation with the
radical scavengers DMSO or penicillamine reduces KYNA formation. No
KYNA was detected when any of the reagents was incubated alone. See
text for further experimental details. Data (mean ± SEM of 6 experiments
per group) represent the KYNA concentration in 500 µl. *P < 0.05 vs.
L-KYN + OH• or ONOO−, #P < 0.05 vs. D-KYN + OH• or ONOO−
(one-way analysis of variance (ANOVA) followed by Tukey’s post hoc
test).
which did not contain measurable amounts of KYNA itself,
reduced KYNA production from OH• + L-KYN or OH• + D-
KYN by 65.8 ± 2.3% and 80.7 ± 1.0%, respectively (Figure 1A).
KYNA production was substantially more pronounced following
the co-incubation of either L-KYN or D-KYN with ONOO−
(25µM). No KYNA was detectable when ONOO− was incubated
on its own (not shown). Addition of the ONOO− scavenger
DL-penicillamine (300 µM), which did not contain KYNA on
its own, decreased KYNA production from either of the two
enantiomers by 78.5 ± 0.7% and 80.1 ± 0.8% for L-KYN and
D-KYN, respectively (Figure 1B).
KAT and DAAO Inhibitors Attenuate KYNA
Production from L-KYN and D-KYN in Tissue
Homogenate
Incubation of tissue homogenate with L-KYN (Figure 2A)
and D-KYN (Figure 2B), respectively, resulted in the de novo
production of KYNA. The KYNA levels recovered after 2 h
incubation with 100 µM of the enantiomers were 18.1 ± 2.9-
fold and 9.8 ± 0.7-fold higher, respectively, than basal levels.
Incubation in the presence of the KAT inhibitor AOAA (1 mM)
reduced KYNA formation from L-KYN and D-KYN by 85.1 ±
1.7% and 27.1 ± 4.5%, respectively, suggesting differences in
the mechanisms by which the two enantiomers are converted
to KYNA in the cerebellum. In line with this conclusion, the
DAAO inhibitors kojic acid, benzoic acid and MPC (all at
1 mM) reduced the production of KYNA from D-KYN by∼66%
(Figure 2B) but did not inhibit KYNA formation from L-KYN
(Figure 2A).
ONOO− Potentiates KYNA Production from
L-KYN and D-KYN in Tissue Homogenate:
Attenuation by KAT and DAAO Inhibitors
The addition of ONOO− (25 µM) to tissue homogenate
increased KYNA production from both L-KYN and D-
KYN (each 100 µM) 2.6 ± 0.3 and 2.8 ± 0.3 times,
respectively (Figure 3). Under these conditions, the presence of
AOAA (1 mM) attenuated the ONOO−-induced potentiation
of KYNA formation from L-KYN (Figure 3A) but not
from D-KYN (Figure 3B). DAAO inhibitors (all at 1 mM)
decreased KYNA production induced by the co-incubation of
both L-KYN and D-KYN with ONOO−, though the effect
of MCP vs. L-KYN + ONOO− did not reach statistical
significance. Kojic acid and benzoic acid were particularly
effective, reducing the total KYNA generated by the combination
of D-KYN + ONOO− by 86.1 ± 2.0% and 75.6 ± 2.7%,
respectively.
Effect of L-KYN and D-KYN on Extracellular
KYNA in vivo
We next designed microdialysis experiments to investigate the
conversion of L-KYN or D-KYN to KYNA in the rat cerebellum
in vivo. The enantiomers were infused for 2 h by reverse dialysis,
and the content of KYNA was monitored in microdialysate
samples for an additional 4 h. Perfusion with 100 µM L-KYN
reversibly raised extracellular KYNA levels, reaching a maximum
of 17.9 ± 3.7 times baseline levels 2 h after the beginning of the
perfusion (Figure 4). Perfusion with 100 µM D-KYN produced
a 10.7 ± 1.2-fold increase in extracellular KYNA levels after 2 h
(Figure 5).
ONOO− Enhances KYNA Production in vivo
A brief (30 min) perfusion with 50 µM ONOO− enhanced
the concentration of extracellular KYNA, assessed by in vivo
microdialysis in the cerebellum. This treatment raised KYNA
levels, assessed in a single 30-min microdialysis fraction, from a
basal value of 2.9± 0.3 nM to 11.4± 2.4 nM (n = 16; P < 0.01).
ONOO− Enhances KYNA Production from L-KYN
and D-KYN in vivo
The 30-min pre-perfusion with ONOO− substantially enhanced
KYNA production from L-KYN or D-KYN (100 µM each)
when the enantiomers were applied by reverse dialysis for 2
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FIGURE 2 | Effect of KAT and DAAO inhibition on KYNA
production from L-KYN or D-KYN (100 µM each) in cerebellar
tissue homogenate. Enzyme inhibitors were used at 1 mM. See text
for further experimental details. Data are expressed as a percentage of
endogenous tissue levels of KYNA (control; 26.4 ± 2.2 pmoles
KYNA/mg protein) and represent the mean ± SEM of 8 experiments
per group. *P < 0.05 vs. control, #P < 0.05 vs. L-KYN (A) or D-KYN
(B) alone (one-way ANOVA followed by Tukey’s post hoc test). AOAA:
Aminooxyacetic acid, KA: kojic acid, BA: benzoic acid, MPC:
3-methylpyrazole-5-carboxylic acid.
FIGURE 3 | ONOO− (25 µM) enhances the production of KYNA from
L-KYN or D-KYN (100 µM each) in cerebellar tissue homogenate. The
effects of KAT and DAAO inhibitors were tested at 1 mM. See text for further
experimental details. Data (mean ± SEM of 8 experiments per group) are
expressed as a percentage of endogenous tissue levels of KYNA (control; 26.4
± 2.2 pmoles/mg protein). *P < 0.05 vs. control, #P < 0.05 vs. L-KYN (A) or
D-KYN (B), &P < 0.05 vs. L-KYN + ONOO− (A) or D-KYN + ONOO− (B)
(one-way ANOVA followed by Tukey’s post hoc test). AOAA: Aminooxyacetic
acid, KA: kojic acid, BA: benzoic acid, MPC: 3-methylpyrazole-5-carboxylic
acid.
h immediately following the termination of perfusion with the
pro-oxidant. In both cases, stimulation was greatest in the first
30 min and subsided gradually with time, probably indicating the
waning influence of the discontinued perfusion with ONOO−
(Figures 4, 5). Peak potentiation, compared to control animals
perfused without ONOO− pre-treatment, was 4.1 ± 1.1-fold for
L-KYN (Figure 4) and 3.2± 0.6-fold for D-KYN (Figure 5).
Discussion
The present study demonstrated that KYNA can be synthesized
enzymatically from both L-KYN and D-KYN in the rat
cerebellum and, furthermore, that KYNA production from either
enantiomer is enhanced in the presence of ROS. These results,
which were first obtained in vitro and then confirmed in vivo,
suggest that KYNA levels in the cerebellum can normally be
controlled by several biosynthetic mechanisms. Conceivably, the
relative significance of these biosynthetic routes may differ under
various physiological conditions as well as in various pathological
situations involving the cerebellum.
Irreversible transamination of L-KYN by KATs is considered
the main means of KYNA formation in the mammalian brain
(Turski et al., 1989) and was verified in the present study using
the non-specific KAT inhibitor AOAA as an experimental tool.
However, D-KYN, too, can serve as a substrate of KATs in both
peripheral tissues and the brain (Pérez-de la Cruz et al., 2012),
and this comparatively minor synthesis route was confirmed
here using cerebellar tissue homogenates. Moreover, in contrast
to L-KYN, D-KYN is an excellent substrate of DAAO, which
is highly concentrated in the cerebellum (Horiike et al., 1994;
Moreno et al., 1999; Verrall et al., 2007). We were therefore not
surprised to observe that the cerebellar production of KYNA
from D-KYN was quantitatively similar to KYNA formation
from L-KYN both in vitro and in vivo, and that the three DAAO
inhibitors BA, KA and MPC all caused a substantial reduction in
KYNA synthesis from D-KYN.
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FIGURE 4 | Effect of reverse dialysis of ONOO− (50 µM) and/or L-KYN
on extracellular KYNA production in the rat cerebellum in vivo. After a
30 min infusion of ONOO− (red bar), L-KYN (100 µM) was infused for 2 h
(black bar; n = 6). In separate rats (n = 8), L-KYN (100 µM) was applied
without pre-treatment. Results (mean ± SEM) are expressed as a percentage
of basal values (3.2 ± 0.4 nM). *P < 0.05 vs. baseline, #P < 0.05 vs. L-KYN
alone (two-way ANOVA followed by paired Student’s t-test was used to
compare the treatment effect at a specific timepoint vs. baseline; and
Student’s t-test was used to compare ONOO− + L-KYN vs. L-KYN alone at a
specific timepoint).
Our study also showed that the redox environment has a
substantial influence on KYNA production in the cerebellum
since the pro-oxidant agents OH• and ONOO− enhanced KYNA
formation from either L-KYN or D-KYN in an artificial milieu
in vitro. As the effect of ONOO− exceeded the effect of OH•,
this pro-oxidant was then tested in cerebellar tissue homogenate
where it greatly potentiated the ability of both KYN enantiomers
to synthesize KYNA. Notably, subsequent in vivo experiments
revealed a substantial increase in extracellular KYNA within
30 min after reverse dialysis of ONOO− alone, suggesting that
a pro-oxidative environment also stimulates the conversion of
endogenous tryptophan or KYN to KYNA (cf. Introduction).
Tryptophan, through its metabolites indole-3-pyruvic acid and
KYN, and the subsequent production of the anti-oxidant KYNA
(Politi et al., 1991; Lugo-Huitrón et al., 2011b; Ugalde-Muniz
et al., 2012), may therefore provide a defense mechanism against
the detrimental effects of ROS in the brain (see below). Also
of note in this context, L-KYN reduces chemiluminescence of
luminol induced by H2O2 or chloramine (Weiss et al., 2013) and
is able to inhibit ROS production by neutrophils (Genestet et al.,
2014).
ROS and reactive nitrogen species (RNS) are produced during
physiological processes and, by interacting with proteins, fatty
acids and DNA, perform numerous roles in the regulation
of cellular function (Dröge, 2002; Koskenkorva-Frank et al.,
2013). Increased production of ROS and RNS and/or insufficient
endogenous defense mechanisms in neurons or astrocytes
can lead to functional impairments and cause cellular injury
(Dringen et al., 2000; Valko et al., 2007; Scherz-Shouval and
Elazar, 2011). Specifically, ONOO− is a potent, short-lived
FIGURE 5 | Effect of reverse dialysis of ONOO− (50 µM) and/or D-KYN
on extracellular KYNA production in the rat cerebellum in vivo. After a
30 min infusion of ONOO− (red bar), D-KYN (100 µM) was infused for 2 h
(black bar; n = 8). In separate rats (n = 11), D-KYN was applied without
pre-treatment. Results (mean ± SEM) are expressed as a percentage of basal
values (2.9 ± 0.5 nM). *P < 0.05 vs. baseline, #P < 0.01 vs. D-KYN alone
(two-way ANOVA followed by paired Student’s t-test was used to compare the
treatment effect at a specific timepoint vs. baseline; and Student’s t-test was
used to compare ONOO− + D-KYN vs. D-KYN alone at a specific timepoint).
oxidant species that is produced by the reaction of nitric oxide
(NO•) and superoxide (O2•−). As NO• is a relatively stable
and highly diffusible free radical (Szabó et al., 2007; Botti et al.,
2010), the formation of ONOO− is spatially associated with
the sources of O2•− (such as the mitochondrial respiratory
complex). This allows ONOO− to inhibit antioxidant enzymes
or neutralize antioxidants (Ischiropoulos et al., 1992; Quijano
et al., 1997; MacMillan-Crow et al., 1998; Aykaç-Toker et al.,
2001; Savvides et al., 2002) and, consequently, to cause apoptotic
or necrotic cell death (Szabó et al., 2007; Franco et al., 2013).
Additionally, ONOO− produces secondary reactive species such
as nitrogen dioxide, hydroxyl and carbonate radicals, all of
which interfere with a large number of cellular functions and
increase cellular vulnerability (Radi et al., 1991; Bartesaghi
et al., 2006). Interestingly, in the present study all three DAAO
inhibitors attenuated KYNA production in the presence of
ONOO− in vitro to various degree (Figure 3), indicating that
these compounds also have antioxidant activity (see also Gomes
et al., 2001).
In the brain, dysregulated redox processes have been
proposed to constitute a critical factor in the pathophysiology
of neurodegenerative disorders and in major psychiatric diseases
including schizophrenia and depressive disorders (Okusaga,
2013; Cahill-Smith and Li, 2014; Salim, 2014; Black et al., 2015;
Gu et al., 2015). Notably, oxidative stress in the brain increases
with advancing age (Tian et al., 1998), so that redox phenomena
may also play a causative role in age-related structural and
cognitive deficits (Dröge and Schipper, 2007; Brawek et al., 2010).
As abnormal cerebral disposition of KYNA, too, has been linked
to various brain pathologies (for review, see Schwarcz et al.,
2012), the present findings raise the possibility that the boosting
of brain KYNA levels by ROS and/or RNS may be functionally
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FIGURE 6 | Routes of KYNA formation. The canonical pathway is initiated by
the oxidative degradation of tryptophan to L-KYN and the subsequent
irreversible transamination of L-KYN to KYNA. Alternative routes to KYNA
involve interactions between tryptophan, L-KYN and D-KYN, respectively, and
ROS. Moreover, DAAO can convert D-KYN to KYNA. Fluctuations in KYNA
levels can alter glutamatergic, dopaminergic, GABAergic and cholinergic
neurotransmission, and may thus be causally involved in cognitive impairments
in aging and major brain diseases.
related to the pathological effects of the pro-oxidants. In other
words, we speculate that the increased generation of KYNA
in the presence of harmful free radicals may have evolved
as a (neuro)protective mechanism to counter the effects of
oxidative stress (Lugo-Huitrón et al., 2011a; Ugalde-Muniz
et al., 2012). This increase in brain KYNA levels may also
have detrimental consequences, however. Thus, even relatively
modest elevations in brain KYNA cause a reduction in the
extracellular concentrations of several classic neurotransmitters,
including dopamine, glutamate and GABA (Carpenedo et al.,
2001; Rassoulpour et al., 2005; Wu et al., 2010; Beggiato
et al., 2014), and may therefore have adverse effects, especially
on cognitive functions (Pocivavsek et al., 2011, 2012). This
hypothesis, as well as the detailed cellular, subcellular and
molecular mechanisms involved in the interactions between
KYNA, ROS and RNS, is currently under investigation in our
laboratories.
Our results also raise the question of a possible role of
D-tryptophan or D-KYN in this context. Thus, whereas the
biology of the essential amino acid L-tryptophan and its
major catabolic product, L-KYN, in mammalian systems is
reasonably well understood, information about possible roles
of their respective D-enantiomers is still very sparse. In fact,
D-KYN has so far not been identified as an endogenous
constituent of mammalian tissues, though it is readily produced
from D-tryptophan, which can originate from the microbial
flora (Friedman, 1999; Rodríguez-Crespo, 2008), from the
diet (Friedman, 2010) or, possibly, from enzymatic cleavage
of D-tryptophan-containing polypeptides, which are found
in several vertebrate species including humans (Jilek et al.,
2005). Experimentally, D-KYN formation from D-tryptophan,
and further degradation to KYNA, has been documented in
several mammalian species and in several organs including
the brain (Tashiro et al., 1961; Higuchi and Hayaishi, 1967;
Loh and Berg, 1971; Ishii et al., 2010; Notarangelo et al.,
2013). Importantly, in line with the high DAAO activity of the
cerebellum (Horiike et al., 1994; Verrall et al., 2007), KYNA
production from systemically applied D-tryptophan or D-KYN
is especially pronounced in the cerebellum (Wang et al., 2012;
Notarangelo et al., 2013). Oxidative processes in this brain
region, which may play a substantive role in a considerable
number of grave neurological and psychiatric diseases including
cerebellar ataxia and autism (Chauhan and Chauhan, 2006;
Kern and Jones, 2006; Wang et al., 2011; Goldani et al.,
2014; Rossignol and Frye, 2014; Salim, 2014; Steullet et al.,
2014), could therefore conceivably have etiological links to
both L-KYN and D-KYN or their respective bioprecursors.
These links could be especially relevant in situations involving
dysfunctions of the immune system, since increased D-KYN
formation from D-tryptophan, as well as enhanced L-KYN
formation from L-tryptophan, is seen under inflammatory
conditions due to a pronounced up-regulation of the non-
stereospecific enzyme indoleamine-2, 3-dioxygenase (Johnson
et al., 2009).
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The fact that the cerebellum can produce KYNA by routes
other than the canonical pathway has likely functional
implications since both α7nAChR and NMDAR, which
can serve as targets of KYNA (Kessler et al., 1989; Hilmas
et al., 2001; Alkondon et al., 2011), are abundant in this
area of the brain (Caruncho et al., 1997; Dumas, 2005;
Llansola et al., 2005; Taslim and Saeed Dar, 2011). While
early experiments, performed mostly using cultured cerebellar
neurons, clearly documented inhibition of NMDAR function
by high (millimolar) concentrations of KYNA (Gallo et al.,
1987; Brockhaus and Deitmer, 2002), recent studies suggest
that α7nAChRs may, in fact, be the preferential target of
endogenous KYNA in the cerebellum. Thus, increases in
cerebellar KYNA concentrations in the nanomolar range
reduce extracellular glutamate levels locally in vivo and, as
also seen in several regions of the forebrain (Albuquerque
and Schwarcz, 2013), this effect can be duplicated by other
α7nAChR—but not NMDAR—antagonists (Wu and Schwarcz,
2013 and unpublished data). Interestingly, and in line with
the well-documented network connecting the cerebellum
with the midbrain and the forebrain (Clower et al., 2005;
Mittleman et al., 2008), even a moderate elevation of cerebellar
KYNA levels controls the extracellular levels of glutamate
and dopamine in the distant prefrontal cortex (Wu and
Schwarcz, 2013). Such insights provide a conceptual framework
for studies designed to explore functional links between
(fluctuations in) cerebellar KYNA and motor, cognitive
and other forebrain functions that, are influenced by the
cerebellum (Ichinohe et al., 2000; Hoshi et al., 2005; Akkal et al.,
2007).
In summary, the present study demonstrates that mechanisms
other than the classic enzymatic transamination of L-KYN,
namely DAAO-catalyzed synthesis from D-KYN, and the
interplay between L-KYN or D-KYN (and possibly L-tryptophan
or D-tryptophan) with ROS, can contribute to the formation
of KYNA in the rat cerebellum (Figure 6). These findings have
ramifications for the role of KYNA in cerebellar physiology and
pathophysiology and suggest novel strategies for normalizing
impaired cerebral KYNA function in aging and major brain
diseases.
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